Minocycline + Clindamycin 2% in hydrocortisone 1% lotion + Erlotinib + Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Minocycline + Clindamycin 2% in hydrocortisone 1% lotion + Erlotinib + Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Minocycline + Clindamycin 2% in hydrocortisone 1% lotion + Erlotinib + Topical clindamycin 2%, triamcinolone acetonide 0.1% soln is a phase 2 stage product being developed by Roche for Rash. The current trial status is completed. This product is registered under clinical trial identifier NCT00473083. Target conditions include Rash.
What happened to similar drugs?
1 of 2 similar drugs in Rash were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00473083 | Phase 2 | Completed |
Competing Products
5 competing products in Rash
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topical Dapsone 5% Gel + oral antibiotics | Bristol Myers Squibb | Phase 3 | 40 |
| 0.25 % Miconazole Nitrate Ointment | GSK plc | Approved | 43 |
| CeraVe Baby Diaper Rash Cream + Desitin Maximum Strength Original Paste | Bausch Health | Pre-clinical | 12 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 25 |
| ATR04-484 + Vehicle | Azitra | Phase 1/2 | 29 |